Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to estimate the reporting rate of suspected Adverse Drug Reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda®, respectively, during the Northern Hemisphere (NH) influenza season 2021/22.
The secondary objectives of the study are:
Study duration per participant is maximum 2 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VaxigripTetra® | Participant vaccinated with VaxigripTetra® as per routine clinical practice |
| |
| Efluelda® | Participant vaccinated with Efluelda® as per routine clinical practice |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quadrivalent Influenza Vaccine | Biological | Intramuscular or subcutaneous administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Vaccinees' reporting rate following routine vaccination with VaxigripTetra® and Efluelda® | The vaccinees' reporting rate is expressed as the percentage of vaccinees who reported at least one suspected ADR among the distributed vaccination cards | Within 7 days after vaccination |
| ADR reporting rate following routine vaccination with VaxigripTetra® and Efluelda® | The ADR reporting rate is expressed as the percentage of suspected ADRs among the distributed vaccination cards | Within 7 days after vaccination |
| Measure | Description | Time Frame |
|---|---|---|
| ADR reporting rate according to age group | Within 7 days after vaccination | |
| Vaccinees' reporting rate according to age group | Within 7 days after vaccination | |
Not provided
Individuals who approach the site for vaccination and agree to receive a vaccination card will be included and vaccinated with the respective vaccine brand according to the country of their location, recommendations for the individual vaccines as well as national recommendations.
Not provided
Not provided
Not provided
VaxigripTetra® will be given to adults (including pregnant women) and children aged 6 months and older in Finland. Efluelda® will be given to adults 60 years of age and older in Germany.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Sciences & Operations | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigational Site Number :2-2-002 | Helsinki | 00180 | Finland | |||
| Investigational Site Number :2-2-005 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36448240 | Background | Gandhi-Banga S, Wague S, Shrestha A, Syrkina O, Talanova O, Nissila M, Stuff K, Monfredo C. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22. Influenza Other Respir Viruses. 2023 Jan;17(1):e13071. doi: 10.1111/irv.13071. Epub 2022 Nov 29. |
Not provided
Not provided
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| High-Dose Quadrivalent Influenza Vaccine | Biological | Intramuscular administration |
|
|
| Vaccinees' reporting rate of serious suspected ADRs at any time following vaccination within the EPSS period |
Serious suspected ADRs will be collected from vaccination up to the end of data collection. Data collection ends when 1000 vaccination cards have been distributed (per vaccine brand) plus 2 weeks or 2 months following the first vaccination, whichever comes first. |
| From vaccination to end of data collection (maximum 2 months following first vaccination) |
| Serious suspected ADR reporting rate at any time following vaccination within the EPSS period | Serious suspected ADRs will be collected from vaccination up to the end of data collection. Data collection ends when 1000 vaccination cards have been distributed (per vaccine brand) plus 2 weeks or 2 months following the first vaccination, whichever comes first. | From vaccination to end of data collection (maximum 2 months following first vaccination) |
| Jyväskylä |
| 40100 |
| Finland |
| Investigational Site Number :2-2-004 | Kuopio | 70100 | Finland |
| Investigational Site Number :2-2-003 | Tampere | 33100 | Finland |
| Investigational Site Number :2-2-011 | Turku | 20100 | Finland |
| Investigational Site Number :2760005 | Blankenhain | 99444 | Germany |
| Investigational Site Number :2760008 | Bochum | 44789 | Germany |
| Investigational Site Number :2760001 | Donaueschingen | 78166 | Germany |
| Investigational Site Number :2760011 | Düsseldorf | 40470 | Germany |
| Investigational Site Number :2760007 | Frankfurt am Main | 60329 | Germany |
| Investigational Site Number :2760002 | Fulda | 36037 | Germany |
| Investigational Site Number :2760003 | Grafenrheinfeld | 97506 | Germany |
| Investigational Site Number :2760004 | Haar | 85540 | Germany |
| Investigational Site Number :2760006 | Hamburg | 20099 | Germany |
| Investigational Site Number :2760009 | Wendelstein | 90530 | Germany |
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided